
NATIONAL IMMUNISATION PROGRAM BOARD


AGENDA

Wednesday, 20 June 2024 1:00pm – 2:00pm AEST Webex & Level 1, Meeting room 1, Scarborough House

#	Item	Lead	Reviewer	Duration
s22				
4	National COVID-19 Vaccine Program – status update	Rachelle Davis	Eispeth Kay	20 Mins
s22				

Members	Division / Department Proxy		
Dr Anna Peatt, First Assistant Secretary	National Immunisation Division		
Dave McNally, Assistant Secretary	Immunisation Program Policy		
Rachelle Davis, Assistant Secretary	Supply and Distribution		
Genevieve Donnelly, Assistant Secretary	Provider Engagement, Communications & Compliance		
Kelly Fisher, Assistant Secretary	Immunisation reform		
Samira Hassan, Assistant Secretary	National Medical Stockpile, Health Security & Emergency Management Division		
Mark Roddam, First Assistant Secretary	Primary Care Division		
Trish Garrett, First Assistant Secretary	Service Delivery Division		
Avinash Clarke, Assistant Secretary	Health Protection & Workforce Branch		
Kayla Jordan, Assistant Secretary	Data and Analytics Branch		
Elspeth Kay, Assistant Secretary	Pharmacovigilance Branch		
Leanne Ringwood, Assistant Secretary	Public Information Branch		
Lee Steel, First Assistant Secretary	Department of the Prime Minister and Cabinet		
Martin Rocks, Assistant Secretary	Department of Finance		
Invitee			
s 22	Department of the Prime Minister and Cabinet		
Observer	Work Area		
s 22	Program Management Office, Primary Care and Community Group		
Secretariat	Work Area		
s 22 Director	Program Management Office		
s 22 Secretariat	Program Management Office		
22 Secretariat Program Management Office			





Dashboard


- There has been a nominal increase in vaccination coverage rates but the overall rate for older Australians is still a concern. A long-standing risk around vaccine uptake has been reframed to reflect this.
- Vaccines remain in a surplus of supply to approximately mid-2026.
- Forecast supply gaps of Novavax \$22
 healthcare professionals.
 \$22
 vaccines are currently being managed with
- s22
- As advised in the action items from the last meeting, the 2023 Rapid Review of the 2023 booster program will inform considerations in terms of tailoring communications to the most at-risk population cohorts.


Assurance


 All assurance activities are on track, with the plan and schedule reflecting the current external assurance activity underway through April-May 2024.


Risks and Issues


- Risk workshops were recently undertaken to ensure the program risks are current with effective mitigation strategies. The paper provided to members details all risks for the Division, noting that not all of these risks relate solely to the NCVP.
- One of the action items from the last meeting was to consider whether the overall risk rating should be reviewed in terms of the impact of the NPP not being agreed.
 - This was considered and determined to be a dependency of the NCVP's critical program elements, but not a risk, as it does not affect the current scope of the Tier 1 project which has been approved to run until December 2024.
 - This dependency will be managed and used to inform contingency planning and mapping of sustainability requirements from January 2025 onwards. This dependency has been highlighted on the roadmap under 'program sustainability.'























\$22


Vaccines remain in a surplus of supply, however will move to a sufficient supply environment in 2025. Forecasted supply gaps of Novavax 322


- Forecasted supply gaps of NovavaxSS22
 currently being managed with Health Care Professionals, with supply of Novavax anticipated to resume in early 2025 S22
- Negotiations are underway with manufacturers to secure the most updated vaccines in the latest presentations i.e. JN.1 vaccines (On 26 April 2024, WHO recommend switch to JN.1 strain) and pre-filled syringes 522
 subject to regulatory approvals.
- Early consultation with stakeholders on the Logistics Model Value Assessment is underway, including initial high-level discussions with State and Territory counterparts who have expressed interest in being involved. Requirements continue to be shaped with the procurement process to commence shortly to engage an external contractor to undertake the Value Assessment.




















NATIONAL IMMUNISATION PROGRAM BOARD

Regulatory status of COVID-19 vaccines and treatments

DATE OF MEETING: 20 J	June	2024
-----------------------	------	------

AGENDA ITEM: 5.1 D: Other Business

s 22	的对于是 数据的现在分			
HART IN PARTY	国际 (水) 是《沙西亚		及公里立法处理	

Regulatory status of COVID-19 vaccines
s 22

 On 21 May 2024 Biocelect Pty Ltd on behalf of Novavax Inc withdrew its application to fully register NUVAXOVID XBB.1.5 COVID-19 vaccine. This was a decision of the sponsor.

s 22

